JDQ443 clinical trials
Also written JDQ443.
How each study uses JDQ443 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
Novartis Pharmaceuticals (5) · Canadian Cancer Trials Group (1) · Maastricht University Medical Center (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test JDQ443.
- Dec 2026Neoadjuvant Platform Trial in Non-Small Cell Lung CancerPhase 2 · Canadian Cancer Trials Group
- Jan 2027Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationPhase 1/2 · Novartis Pharmaceuticals
Studies
Open first, then newest update. How each study uses JDQ443 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerTerminatedPhase 3Novartis PharmaceuticalsNCT05132075Written as JDQ443
- Neoadjuvant Platform Trial in Non-Small Cell Lung CancerActive, not recruitingPhase 2Canadian Cancer Trials GroupNCT05714891Written as JDQ443
- Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsActive, not recruitingPhase 1/2Novartis PharmaceuticalsNCT07468071Written as Opnurasib
- Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationActive, not recruitingPhase 1/2Novartis PharmaceuticalsNCT04699188Written as JDQ443
- Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.Active, not recruitingPhase 2Novartis PharmaceuticalsNCT05445843Written as JDQ443
- A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.CompletedPhase 1Novartis PharmaceuticalsNCT05329623Written as JDQ443
- JDQ443 for KRAS G12C NSCLC Brain MetastasesWithdrawnPhase 2Maastricht University Medical CenterNCT05999357Written as JDQ443
Given beside what is tested · 1 — JDQ443 is usual care or a partner of the new treatment
Codes
What other systems call JDQ443 · ClinicalTrials.gg INT002010
- MeSH (NLM) C000726658JDQ443One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000726658 | JDQ443 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.